8-K: Supernus Pharmaceuticals to Announce Q4 and Full Year 2024 Results on February 25, 2025

Supernus Pharmaceuticals will release its fourth quarter and full year 2024 financial results after market close on February 25, 2025, followed by a conference call and webcast.

Summary

• Supernus Pharmaceuticals, Inc. will report its financial and business results for the fourth quarter and full year 2024 after the market closes on Tuesday, February 25, 2025.
• A conference call and webcast will be held on the same day at 4:30 p.m. E.T. to discuss the results.
• The call will include prepared remarks from management, a discussion of business results, and a Q&A session.
• A live webcast will be accessible via the company's Investor Relations website, and a replay will be available for 60 days following the live call.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it's a routine announcement of an upcoming earnings call. The company is providing transparency and access to information for investors.

Positives

• Supernus Pharmaceuticals is providing investors with a timely update on its financial performance.
• The company is offering multiple channels for investors to access the information, including a conference call and webcast.
• A replay of the webcast will be available for an extended period, allowing investors to review the information at their convenience.

Future Outlook

The company will provide insights into its future outlook during the conference call and webcast on February 25, 2025.

Management Comments

• Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host the conference call.

Industry Context

This announcement is a standard practice for publicly traded companies to keep investors informed about their financial performance. Supernus Pharmaceuticals operates in the biopharmaceutical industry, specifically focusing on central nervous system (CNS) diseases.

Stakeholder Impact

• Shareholders will be informed about the company's financial performance.
• Analysts and investors will have the opportunity to ask questions during the conference call.
• The announcement provides transparency and allows stakeholders to assess the company's progress.

Next Steps

• Supernus Pharmaceuticals will report its Q4 and full year 2024 financial results.
• Management will host a conference call and webcast to discuss the results.
• Investors can access the live webcast or a replay on the company's website.

Key Dates